IL6 and COVID-19: The graph for tocilizumab (ranked first) is shown in Figure 4B. Tocilizumab mainly affects interleukin 6 (IL-6), Janus kinase 2 (JAK2), and signal transducer and activator of transcription 1 (STAT1) [49,50], while it has a therapeutic effect on COVID-19–related inflammation, dyspnea, and autoimmune diseases [51-53].